EBV positive DLBCL, NOS

Ding-Bao Chen

Department of Pathology, Peking University People's Hospital, Beijing 100044, People's Republic of China; cdingbao@163.com

Published in Atlas Database: July 2018

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/EBV_DLBCLID1834.html


DOI: 10.4267/2042/70207

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

Abstract

Epstein-Barr virus positive DLBCL, NOS (EBV + DLBCL, NOS) occurs in apparently immunocompetent patients usually older than 50 years, which can also occur in younger patients and has a worse prognosis than EBV negative tumors. EBV + DLBCL, NOS has a broader morphological spectrum. Here the clinicopathological of EBV positive DLBCL will be discussed.

Keywords

EBV positive DLBCL; immunophenotype; Cytogenetics

Identity

Other names

Senile EBV-associated B-cell lymphoproliferative disorder; age-related EBV+ lymphoproliferative disorder; EBV-associated B-cell lymphoproliferative disorder of the elderly.

Clinics and pathology

Disease


Phenotype/cell stem origin

The neoplastic cells are of B-cell lineage, expressing the pan B-cell antigens CD19, CD20, CD22, CD79a, and PAX5 and are negative for pan T-cell antigens. Immunoglobulin light chain restriction may be difficult to demonstrate, except in cases with immunoblastic or plasmablastic features in which cytoplasmic Ig can be assessed. Plasmacytoid cases can be weakly positive or negative CD20. EBV+ DLBCL of the elderly usually has an ABC immunophenotype being MUM1/IRF41 and CD102 and usually BCL6. BCL-2 and CD30 are usually positive, and CD15 is negative. It is speculated that either there is a change in B-cell population during aging or there is putative pathological specificity of EBV in elderly patients with DLBCL. Most cases displayed a striking shift to an ABC immunophenotype with prominent activation of NF-kB pathway (Swerdlow, et al, 2008. Swerdlow, et al, 2016).

Epidemiology

The median age of patients with EBV+ DLBCL is 71 years (range, 50-91 years), however, younger patients can be affected. There is a slight male predominance, with a male to female ratio of 1.4 :1. There is a higher prevalence of EBV+ DLBCL among East Asians (8.7%-11.4%) compared with 5% in Western countries. The definitive criterion for EBV positivity in EBV+ DLBCL remains under discussion (Swerdlow, et al, 2008).
Clinics
EBV+ DLBCL is characterized by higher age distribution and an aggressive clinical course with a median survival of 2 years in Asian patients. Initial reports emphasized that EBV+ DLBCL of the elderly commonly involved extranodal sites. Site of primary extranodal involvement include the skin, soft tissue, bones, nasal cavity, pharynx/hypopharynx, tonsils, tongue, lung, pleura, stomach, liver, spleen, peritoneum, cecum, and bone marrow. Patients with EBV+ DLBCL of the elderly have a poorer overall survival and progression-free survival than patients with Activated B-cell-like (ABC)-type EBV-negative DLBCL in older European patients (Swerdlow et al, 2008).

Pathology
Two morphologic subtypes of EBV+ DLBCL have been recognized: polymorphic and monomorphin. Both subtypes may include large transformed cells or immunoblasts, as well as HRS-like giant cells and may demonstrate increased mitotic activity and areas of geographic necrosis. The polymorphic subtype displays a broad range of B-cell maturation, and lesions are composed of centroblasts, immunoblasts, and plasmablasts with a variable component of admixed reactive cells, including small lymphocytes, plasma cells, histiocytes, and epithelioid histiocytes. The monomorphic subtype of EBV+ DLBCL of the elderly is composed of monotonous sheets of large transformed B cells. Cases of EBV+ DLBCL of the elderly also can have a mixed pattern with intermingled polymorphic/and monomorphic areas, suggesting that the subtypes represent 2 ends of a morphologic spectrum.

Figure 1. EBV+ DLBCL, polymorphic subtype. A broad range of B-cell maturation, composed of centroblasts, immunoblasts, and plasmablasts with a variable component of admixed reactive cells (HE staining).

Figure 2. EBV+ DLBCL, monomorphic subtype. Sheets of large transformed B cells (HE staining).
**Treatment**

EBV+ DLBCLs, including EBV+DLBCL of the elderly, respond more poorly to treatment with a poorer outcome compared with patients who have EBV-negative DLBCL. Novel therapeutic approaches need to be considered for patients with EBV+ DLBCL. Possible therapeutic approaches include (1) EBV-specific adoptive immunotherapy; (2) miRNA-targeted therapy; (3) combination therapy based on EBV lytic phase induction followed by exposure of the tumor cells to antiherpvsirus drugs (Swerdlow et al, 2008. Swerdlow, et al., 2016). Less toxic treatment strategy such as a cell therapy for EBV-specific viral antigens will be needed and should be evaluated in clinical trials (Oyama T et al., 2007).

**Prognosis**

Young patients present with nodal disease and have a good prognosis (Nicolae A et al., 2015). The International prognostic index (IPI) and the Oyama score can be used for risk-stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor (Castillo JJ et al., 2018). In contrast to non-Western populations, the North American population had a low prevalence of EBV+ DLBCL that did not convey an adverse prognosis. A history of immunosuppression, while known to be a risk factor for the development of diffuse large B-cell lymphoma, did not affect subsequent prognosis (Tracy SI et al., 2018).
EBV positive DLBCL, NOS

Cytogenetics

Note
Only a few genetic studies on cases of EBV+DLBCL have been performed. The immunoglobulin genes are monoclonally rearranged in most cases, with clonality of EBV also usually detectable using EBV terminal repeat regions probes and molecular techniques. IGH-mediated translocations are uncommon (15%). However, these analyses were restricted to single loci (IGH, IGK, IGL, PAX5, MYC, BCL2, and BCL6). Given the presence of a low number of genomic aberrations in EBV+DLBCL, it has been suggested that immunosenesecence coupled with the EBV oncogenic properties is sufficient, and additional chromosomal alterations are therefore usually not needed for lymphomagenesis.

Although viral miRNA constitutes only 2% of all mRNA in EBV-positive DLBCL, the viral miRNAs share seed sequence homology with cellular miRNA. It also becomes evident that EBV miRNAs have evolved to target multiple cellular pathways rather than a single pathway. Interestingly, cellular miRNAs are modulated by viral proteins. MIR155 has been shown in DLBCL, especially in the ABC subtype, and can be induced by PDLIM7 (LMP1) via the NF-kB pathway (Swerdlow, et al., 2008. Ok CY, et al. 2013).

A study showed that the gene expression profiling and microRNA profiles of younger patients with EBV+DLBCL is similar to older patients (Ok CY, et al. 2015).

References


This article should be referenced as such:

Chen DB. EBV positive DLBCL, NOS. Atlas Genet Cytogenet Oncol Haematol. 2019; 23(5):120-123.